Composite hydrogel as well as preparation method and application thereof
By combining photosensitive chitosan, dopamine-modified oxidized polysaccharides and inorganic calcium and silicone materials in bone repair materials, the composite hydrogel loaded with traditional Chinese medicine monomers has been solved. The deficiencies of existing hydrogels in bone repair are solved. , achieving the effects of pro-bone differentiation, vascularization and sustained release, and improving the performance of bone repair materials.
Patent Information
- Application Number
- CN202411314131.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-12-06
AI Technical Summary
Existing hydrogels lack the biological activity of pro-angiogenesis and pro-osteogenesis in bone repair, lack of degradability, and fail to effectively promote bone regeneration and vascularization.
Photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides and inorganic calcium and silicon materials are combined. The Chinese medicine monomer is loaded in a composite hydrogel, providing mechanical support through photosensitive chitosan, and dopamine-modified oxidized polysaccharides improve adhesion and Early degradation, inorganic calcium silicon material promotes bone differentiation and vascularization, and achieves sustained release effect through crosslinking agents.
The good osteopromoting differentiation, vascularization effect, adhesion performance and degradation performance of the composite hydrogel are achieved, avoiding the problem of sudden drug release, and improving the rigidity and continuous osteopromoting effect of bone repair materials.
Smart Images

Figure CN119075002A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of hydrogel materials, and particularly relates to a composite hydrogel and a preparation method and application thereof. Background Art
[0002] Critical bone defects caused by trauma, infection, pathological factors (such as tumor resection), congenital defects, etc. usually require medical intervention, such as bone repair, to achieve healing. In bone repair, promoting angiogenesis and osteogenesis are the key points and difficulties, while simple hydrogel scaffolds lack the biological activity of promoting angiogenesis and osteogenesis.
[0003] A study proposed a bone regeneration hydrogel and its preparation method and application. The bone regeneration hydrogel includes a photosensitive chitin derivative and a trace element doped calcium silicate. This technology improves bone inductivity by doping calcium silicate with trace elements. However, its degradability still needs to be improved to match the regeneration speed of bone repair; in addition, this study did not disclose its vascularization and drug loading properties.
[0004] Therefore, it is of great significance to provide a composite hydrogel with good osteogenic differentiation, vascularization effect and suitable degradation performance. Summary of the invention
[0005] The present invention aims to solve one or more technical problems existing in the above-mentioned prior art, and at least provide a beneficial choice or create conditions. Specifically, the present invention provides a composite hydrogel, which has good osteogenic differentiation, vascularization effect, adhesion performance and suitable degradation performance.
[0006] The inventive concept of the present invention: the composite hydrogel of the present invention comprises photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides, inorganic calcium silicon materials, crosslinking agents and Chinese medicine monomers; the Chinese medicine monomers are loaded in the photosensitive chitosan or its derivatives, the dopamine-modified oxidized polysaccharides and / or the inorganic calcium silicon materials. The present invention constructs a matrix with a certain mechanical strength through photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides provide adhesion and achieve early degradation, and the inorganic calcium silicon materials promote osteogenic differentiation and vascularization. In addition, the present invention enables the composite hydrogel to have a sustained release property by loading the Chinese medicine monomers in the photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides and / or inorganic calcium silicon materials, and can slowly release the Chinese medicine monomers that promote bone repair, avoiding the problem of sudden release of drugs directly loaded in the hydrogel and failing to continuously provide sufficient bone induction signals, and can also improve the rigidity of the composite hydrogel.
[0007] Therefore, a first aspect of the present invention provides a composite hydrogel.
[0008] Specifically, the composite hydrogel includes photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharide, inorganic calcium silicon material, a cross-linking agent and traditional Chinese medicine monomers;
[0009] The traditional Chinese medicine monomer is loaded in the photosensitive chitosan or its derivative, the dopamine-modified oxidized polysaccharide and / or the inorganic calcium silicon material.
[0010] Specifically, photosensitive chitosan or its derivatives can provide mechanical support for the scaffold. Dopamine-grafted polysaccharides can mimic the adhesion mechanism of mussel byssus, improve adhesion performance, improve the adhesion of bone implant materials, and facilitate their fixation in bone defects. At the same time, photosensitive chitosan or its derivatives can provide mechanical support for bone implant materials, and utilize the adhesion mechanism of dopamine-grafted polysaccharides so that bone implant materials can fully fill bone defects after adhering to bone defects, thereby promoting bone repair. Inorganic calcium silicon materials contain Ca 2+ 、Si 4+ Plasma can regulate the expression of angiogenesis-related biological molecules and promote angiogenesis. It works synergistically with photosensitive chitosan or photosensitive chitosan derivatives and dopamine-modified oxidized polysaccharides to make the composite hydrogel have excellent osteogenic differentiation performance, angiogenesis effect and mechanical properties.
[0011] Preferably, the photosensitive chitosan derivative includes at least one of photosensitive quaternized chitosan and photosensitive carboxymethyl chitosan.
[0012] Preferably, the dopamine-modified oxidized polysaccharide includes at least one of dopamine-modified oxidized hyaluronic acid, dopamine-modified oxidized chondroitin sulfate, and dopamine-modified oxidized dextran.
[0013] Preferably, the inorganic calcium silicon material includes at least one of calcium silicate, bioglass, calcium-doped silicon dioxide, calcium-doped zinc silicate, calcium-doped magnesium silicate, and calcium-doped strontium silicate.
[0014] Preferably, the traditional Chinese medicine monomer includes at least one of notoginseng saponins, salvianolic acid, quercetin, ginsenosides, icariin, paridis saponins, hesperidin, ferulic acid, and curcumin.
[0015] Preferably, in the composite hydrogel, the mass fraction of the photosensitive chitosan or its derivative is 0.1-11%; further preferably, the mass fraction of the photosensitive chitosan or its derivative is 0.1-10%; further preferably, the mass fraction of the photosensitive chitosan or its derivative is 1%, 1.33%, 3% or 6%.
[0016] Preferably, in the composite hydrogel, the mass fraction of the dopamine-modified oxidized polysaccharide is 0.1-11%; further preferably, the mass fraction of the dopamine-modified oxidized polysaccharide is 0.1-10%; further preferably, the mass fraction of the dopamine-modified oxidized polysaccharide is 1.25%, 2.5% or 5%.
[0017] Preferably, in the composite hydrogel, the mass fraction of the inorganic calcium silicon material is 0.1-11%; further preferably, the mass fraction of the inorganic calcium silicon material is 0.1-10%; further preferably, the mass fraction of the inorganic calcium silicon material is 1%, 1.67%, 2.5% or 5%.
[0018] Preferably, in the composite hydrogel, the loading mass fraction of the traditional Chinese medicine monomer is 0.0001-11%; further preferably, the loading mass fraction of the traditional Chinese medicine monomer is 0.005-1%; further preferably, the loading mass fraction of the traditional Chinese medicine monomer is 0.08%, 0.25%, 0.4%, 0.8%, 5% or 10%.
[0019] Preferably, the cross-linking agent comprises a photoinitiator.
[0020] Preferably, the photoinitiator includes at least one of 2-hydroxy-2-methyl-1-[4-(2-hydroxyethoxy)phenyl]-1-propanone (I2959) and phenyl-2,4,6-trimethylbenzoyl lithium phosphite (LAP); further preferably, the photoinitiator is LAP.
[0021] The second aspect of the present invention provides a method for preparing the composite hydrogel according to the first aspect of the present invention.
[0022] Specifically, the preparation method of the composite hydrogel comprises the following steps:
[0023] The Chinese medicine monomer is loaded into the photosensitive chitosan or its derivatives, dopamine-modified oxidative active polysaccharide and / or inorganic calcium silicon material to obtain a mixture; then the mixture is mixed with the remaining components and solidified to obtain the composite hydrogel.
[0024] Preferably, after the mixture is mixed with the remaining components, a suspension is obtained; in the suspension, the concentration of the photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharide, and inorganic calcium silicon material is the same as the mass fraction of each component in the above-mentioned composite hydrogel, and the loading mass fraction of the traditional Chinese medicine monomer is the same as the loading mass fraction of the traditional Chinese medicine monomer in the above-mentioned composite hydrogel.
[0025] Preferably, the curing time is 0.5s-30min; further preferably, the curing time is 5s-1min.
[0026] The curing time is the gel time of the composite hydrogel.
[0027] Preferably, the adhesion strength of the composite hydrogel is 18-33 kPa; further preferably, the adhesion strength of the composite hydrogel is 20-30 kPa.
[0028] A third aspect of the present invention provides a bone repair material.
[0029] Specifically, the bone repair material includes the composite hydrogel described in the first aspect of the present invention.
[0030] The fourth aspect of the present invention provides a use of the composite hydrogel described in the first aspect of the present invention in the preparation of medical materials.
[0031] Compared with the prior art, the technical solution provided by the present invention has the following beneficial effects:
[0032] (1) The present invention enables the composite hydrogel to have good osteogenic differentiation, vascularization effect, adhesion performance and degradation performance through the combined action of photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides and inorganic calcium silicon materials. In addition, the present invention enables the composite hydrogel to have sustained release performance by loading Chinese medicine monomers on the photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides and / or inorganic calcium silicon materials, and can slowly release Chinese medicine monomers that promote bone repair, achieve a continuous osteoinduction effect, and also improve the rigidity of the composite hydrogel.
[0033] (2) The composite hydrogel of the present invention can be effectively injected to fill irregularly shaped bone defects, and then illuminated to allow the photosensitive chitosan or its derivatives to undergo Schiff base cross-linking with dopamine-modified oxidized polysaccharides. The composite hydrogel can adhere well to bone tissue and promote bone defect repair. It is easy to operate and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0034] Figure 1 The scanning electron microscope images of the composite hydrogels of Example 1 and Comparative Examples 1-2 of the present invention are shown;
[0035] Figure 2 The elastic modulus result diagram of the composite hydrogel of Example 1 and Comparative Examples 1-2 of the present invention;
[0036] Figure 3 This is a graph showing the adhesion performance test results of the composite hydrogels of Example 1 and Comparative Examples 2-3 of the present invention;
[0037] Figure 4 The in vitro degradation effect diagram of the composite hydrogel of Example 1 and Comparative Example 1-2 of the present invention;
[0038] Figure 5The release performance curves of drugs and ions in the composite hydrogels of Example 1 and Comparative Example 2 of the present invention are as follows;
[0039] Figure 6 The figure is a graph showing the proliferation of rBMSCs cells in the composite hydrogel extracts of Comparative Examples 1-2 and Example 1;
[0040] Figure 7 This is a diagram showing the proliferation of HUVECs cells in the composite hydrogel extracts of Comparative Examples 1-2 and Example 1;
[0041] Figure 8 This is a graph showing the in vitro osteogenic differentiation performance of the composite hydrogels of Example 1 and Comparative Examples 1-2 of the present invention;
[0042] Fig. 9 This is a graph showing the in vitro angiogenesis performance of the composite hydrogels of Example 1 and Comparative Examples 1-2 of the present invention. DETAILED DESCRIPTION
[0043] In order to make the technical scheme of the present invention more clearly understood by those skilled in the art, the following embodiments are listed for illustration. It should be pointed out that the following embodiments do not limit the protection scope of the present invention.
[0044] Unless otherwise specified, the raw materials, reagents or devices used in the following examples can be obtained from conventional commercial sources or by existing known methods.
[0045] Example 1
[0046] A method for preparing a composite hydrogel loaded with a traditional Chinese medicine monomer notoginseng saponin Ft1 comprises the following steps:
[0047] (1) Construction of drug-loaded matrix: The hollow mesoporous bioglass was immersed in a notoginseng saponin Ft1 / ethanol solution for 3 h; then centrifuged and dried to obtain a mesoporous bioglass loaded with notoginseng saponin Ft1 (Ft1-BG); the drug loading amount of Ft1 in the hollow mesoporous bioglass was 4.76%;
[0048] (2) Construction of composite hydrogel: 20 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 18.75 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 25 mg of Ft1-BG obtained in step (1) was ultrasonically dispersed in 125 μL of ultrapure water, and then dropwise added to liquid A, and then liquid B was added to liquid A, mixed evenly, to obtain a mixed solution; the mixed solution was then injected into a mold and cross-linked with blue light at 37°C for 30 seconds to obtain a composite hydrogel loaded with the traditional Chinese medicine monomer Panax notoginseng saponin Ft1 (denoted as Ft1-BG / Hy, where Hy represents a composite hydrogel constructed of photosensitive chitosan and dopamine-modified hyaluronic acid).
[0049] Example 2
[0050] A method for preparing a composite hydrogel loaded with a traditional Chinese medicine monomer, salvianolic acid, comprises the following steps:
[0051] (1) Construction of drug-loaded matrix: The hollow mesoporous calcium silicate was immersed in a solution of salvianolic acid B / ethanol for 1 hour; then, after centrifugation and drying, the hollow mesoporous calcium silicate loaded with salvianolic acid B was obtained, and the drug loading amount of salvianolic acid B in the hollow mesoporous calcium silicate was 10%;
[0052] (2) Construction of composite hydrogel: 20 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 28.125 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 25 mg of the hollow mesoporous calcium silicate loaded with salvianolic acid B obtained in step (1) was ultrasonically dispersed in 125 μL of ultrapure water, and then dropwise added to liquid A, and then liquid B was added to liquid A, mixed evenly, to obtain a mixed solution; the mixed solution was then injected into a mold, and cross-linked under ultraviolet light at 37°C for 1 min to obtain a composite hydrogel loaded with the traditional Chinese medicine monomer salvianolic acid B.
[0053] Example 3
[0054] A method for preparing a composite hydrogel loaded with a traditional Chinese medicine monomer quercetin comprises the following steps:
[0055] (1) Construction of drug-loaded matrix: The hollow mesoporous calcium silicate was immersed in a quercetin / ethanol solution for 30 min; the particles were then centrifuged and dried to obtain quercetin-loaded mesoporous calcium silicate; the drug loading amount of quercetin in the hollow mesoporous calcium silicate was 5%;
[0056] (2) Construction of composite hydrogel: 15 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 18.75 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 15 mg of the quercetin-loaded mesoporous calcium silicate obtained in step (1) was ultrasonically dispersed in 125 μL of ultrapure water, and then added dropwise to liquid A; liquid B was then added to liquid A, mixed evenly, to obtain a mixed solution; the mixed solution was then injected into a mold, and cross-linked under blue light at 37°C for 30 seconds to obtain a composite hydrogel loaded with the Chinese medicine monomer quercetin.
[0057] Example 4
[0058] A method for preparing a composite hydrogel loaded with Chinese medicine monomer saponin, comprising the following steps:
[0059] (1) Construction of drug-loaded matrix: Calcium-doped silica was immersed in a Paris saponin I / methanol solution for 1.5 h; the particles were centrifuged and dried to obtain calcium-doped silica loaded with Paris saponin I; the drug loading amount of Paris saponin I in the hollow mesoporous calcium silicate was 8%;
[0060] (2) Construction of composite hydrogel: 10 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 37.5 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 45 mg of calcium-doped silica loaded with saponin I obtained in step (1) was ultrasonically dispersed in 125 μL of ultrapure water and added dropwise to liquid A; liquid B was then added to liquid A, mixed evenly, to obtain a mixed solution; the mixed solution was then injected into a mold, and blue light cross-linked at 37°C for 5 min to obtain a composite hydrogel loaded with the Chinese medicine monomer saponin I.
[0061] Example 5
[0062] A method for preparing a composite hydrogel loaded with a traditional Chinese medicine monomer ferulic acid comprises the following steps:
[0063] (1) Construction of drug-loaded matrix: Calcium-doped zinc silicate was immersed in a ferulic acid / ethanol solution for 5 h; the particles were centrifuged and dried to obtain calcium-doped zinc silicate loaded with ferulic acid; the drug loading amount of ferulic acid in calcium-doped zinc silicate was 8%;
[0064] (2) Construction of composite hydrogel: 30 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 22.5 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 75 mg of calcium-doped zinc silicate loaded with ferulic acid obtained in step (1) was ultrasonically dispersed in 125 μL of ultrapure water and added dropwise to liquid A; liquid B was then added to liquid A and mixed evenly to obtain a mixed solution; the mixed solution was then injected into a mold and cross-linked with blue light at 37°C for 15 seconds to obtain a composite hydrogel loaded with ferulic acid, a monomer of traditional Chinese medicine.
[0065] Example 6
[0066] A method for preparing a composite hydrogel loaded with a traditional Chinese medicine monomer hesperidin comprises the following steps:
[0067] (1) Construction of drug-loaded matrix: 25 mg of photosensitive quaternary aminated chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve, and then the hesperidin / ethanol solution was added to obtain a hesperidin-loaded solution (solution A); the drug loading amount of hesperidin in the photosensitive quaternary aminated chitosan was 0.8%;
[0068] (2) Construction of composite hydrogel: 30 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 37.5 mg of calcium-doped zinc silicate was ultrasonically dispersed in 125 μL of ultrapure water and liquid A was added dropwise; liquid B was then added to liquid A and mixed evenly to obtain a mixed solution; the mixed solution was then injected into a mold and cross-linked under ultraviolet light at 37°C for 90 s to obtain a composite hydrogel loaded with the Chinese medicine monomer hesperidin.
[0069] Example 7
[0070] A method for preparing a composite hydrogel loaded with icariin, a traditional Chinese medicine monomer, comprises the following steps:
[0071] (1) Construction of drug-loaded matrix: 50 mg of dopamine-modified oxidized chondroitin sulfate was dissolved in 375 μL of ultrapure water, and then icariin / ethanol solution was added to obtain solution A; the drug loading amount of icariin in solution A was 0.2%;
[0072] (2) Construction of composite hydrogel: 35 mg of photosensitive carboxymethyl chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water and stirred to dissolve to form liquid B; 15 mg of calcium silicate was ultrasonically dispersed in 125 μL of ultrapure water and added dropwise to liquid B; liquid A was then added to liquid B and mixed evenly to obtain a mixed solution; the mixed solution was then injected into a mold and cross-linked with blue light at 37°C for 45 seconds to obtain a composite hydrogel loaded with the Chinese medicine monomer icariin.
[0073] Example 8
[0074] A method for preparing a composite hydrogel loaded with a traditional Chinese medicine monomer, salvianolic acid B, comprises the following steps:
[0075] (1) Construction of drug-loaded matrix: Calcium-doped silica was immersed in a salvianolic acid B / ethanol solution for 1 h; the particles were centrifuged and dried to obtain calcium-doped silica loaded with salvianolic acid B; the drug loading amount of salvianolic acid B in calcium-doped silica was 10%; 40 mg of dopamine-modified oxidized chondroitin sulfate was dissolved in 375 μL of ultrapure water, and then salvianolic acid B / water solution was added to obtain liquid A; the drug loading amount of salvianolic acid B in liquid A was 0.1%;
[0076] (2) Construction of composite hydrogel: 35 mg of photosensitive carboxymethyl chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water and stirred to dissolve to form liquid B; 30 mg of calcium-doped silica loaded with salvianolic acid B was ultrasonically dispersed in 125 μL of ultrapure water and added dropwise to liquid B; liquid A was then added to liquid B and mixed evenly to obtain a mixed solution; the mixed solution was then injected into a mold and cross-linked with blue light at 37°C for 45 s to obtain a composite hydrogel loaded with Chinese medicine monomers.
[0077] Comparative Example 1
[0078] The difference between Comparative Example 1 and Example 1 is that Comparative Example 1 does not contain Ft1-BG.
[0079] Specifically, the preparation method of the composite hydrogel of Comparative Example 1 comprises the following steps:
[0080] 20 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1.125 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 18.75 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; liquid B was added to liquid A and mixed evenly; the mixed solution was then injected into the mold and cross-linked with blue light at 37°C for 30 seconds to obtain a composite hydrogel (denoted as Hy).
[0081] Comparative Example 2
[0082] The difference between Comparative Example 2 and Example 1 is that the composite BG in Comparative Example 2 is not loaded with notoginseng saponin Ft1.
[0083] Specifically, the preparation method of the composite hydrogel of Comparative Example 1 comprises the following steps:
[0084] 20 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 18.75 mg of dopamine-modified oxidized hyaluronic acid was dissolved in 375 μL of ultrapure water to form liquid B; 25 mg of BG was ultrasonically dispersed in 125 μL of ultrapure water, and liquid A was added dropwise, and then liquid B was added to liquid A and mixed evenly; the mixed solution was then injected into the mold and cross-linked with blue light at 37°C for 30 seconds to obtain a composite hydrogel (denoted as BG / Hy).
[0085] Comparative Example 3
[0086] The difference between Comparative Example 3 and Example 1 is that dopamine-modified oxidized hyaluronic acid is not added in Comparative Example 3.
[0087] Specifically, the preparation method of the composite hydrogel of Comparative Example 3 comprises the following steps:
[0088] (1) Construction of drug-loaded matrix: The hollow mesoporous bioglass was immersed in a notoginseng saponin Ft1 / ethanol solution for 3 h; then centrifuged and dried to obtain a mesoporous bioglass loaded with notoginseng saponin Ft1 (Ft1-BG); the drug loading amount of Ft1 in the hollow mesoporous bioglass was 4.76%;
[0089] (2) 20 mg of photosensitive chitosan and 2.5 mg of LAP were added to 1.375 mL of ultrapure water, and then placed in a 4°C water bath and stirred to dissolve to form liquid A; 25 mg of Ft1-BG was ultrasonically dispersed in 125 μL of ultrapure water, and liquid A was added dropwise and mixed evenly; the mixed solution was then injected into the mold and cross-linked with blue light at 37°C for 30 s to obtain a composite hydrogel (denoted as Ft1-BG / CSMA).
[0090] Performance Testing
[0091] 1. Scanning electron microscopy observation
[0092] The composite hydrogels prepared in Comparative Example 1 (Hy), Comparative Example 2 (BG / Hy), and Example 1 (Ft1-BG / Hy) were freeze-dried and then immersed in liquid nitrogen for 1 min. The freeze-dried hydrogel samples were broken to expose the cross section. The hydrogel samples were fixed on a metal table with a conductive double-sided tape to clean the surface dust. Gold was sprayed for 80 s, and the microscopic morphology of the hydrogel was observed using SEM. The scanning electron microscope images of the composite hydrogels in Example 1 and Comparative Examples 1-2 are as follows: Figure 1 As shown, Figure 1 Figure (a) is a scanning electron microscope image of the composite hydrogel of Comparative Example 1; Figure 1 Figure (b) is a scanning electron microscope image of the composite hydrogel of Comparative Example 2; Figure 1 Figure (c) is a scanning electron microscope image of the composite hydrogel of Example 1; Figure 1 Figure (d) is an enlarged view of the red box in Figure (a). Figure 1 Figure (e) is an enlarged view of the red box in Figure (b). Figure 1 Figure (f) is an enlarged view of the red box in Figure (c). Figure 1 The scale bars in (a), (b), and (c) are all 200 μm. Figure 1 The scale bars in (d), (e), and (f) are all 30 μm.
[0093] Depend on Figure 1 It can be seen that compared with Comparative Example 1, after adding BG and Ft1-BG to the composite hydrogel, they are evenly distributed on the pore wall, increasing the roughness of the pore wall. The internal pore size of the composite hydrogel is between 100-200 μm. The addition of BG and Ft1-BG does not affect its pore size, while increasing the roughness, which is suitable for cell encapsulation, cell growth and nutrient exchange, and is conducive to stem cell adhesion and osteogenic differentiation.
[0094] The composite hydrogels loaded with traditional Chinese medicine monomers of Examples 2-8 have similar surface morphologies to those of Example 1, and also have good pore structures and surface morphologies.
[0095] 2. Elastic modulus test
[0096] The compression performance of the photo-crosslinked composite hydrogels of Comparative Example 1 (Hy), Comparative Example 2 (BG / Hy), and Example 1 (Ft1-BG / Hy) was tested using a universal mechanical testing machine. The loading rate was 1 mm / min, and a linear fit was performed on 5%-15% of the sample compression amount. The slope of the fitting line was taken as the elastic modulus. The results are shown in FIG. Figure 2 As shown, where * indicates that there are significant differences between Comparative Example 2 and Example 1 and Comparative Example 1, respectively.
[0097] Depend on Figure 2 It can be seen that the Young's modulus of the Hy composite hydrogel prepared in Comparative Example 1 is about 5.85±1.63KPa under 5%-15% compression conditions; after adding BG and Ft1-BG to Comparative Example 2 and Example 1, respectively, the Young's modulus of the materials increased to 11±2.43KPa and 12±2.03KPa, respectively, and the difference is statistically significant, that is, the rigidity increases.
[0098] In addition, the composite hydrogels loaded with Chinese medicine monomers in Examples 2-8 have an elastic modulus comparable to that in Example 1, that is, the composite hydrogels loaded with Chinese medicine monomers in Examples 2-8 have good rigidity.
[0099] 3. Adhesion performance test
[0100] The adhesion performance of the composite hydrogels of Example 1 (Ft1-BG / Hy), Comparative Example 2 (BG / Hy), and Comparative Example 3 (Ft1-BG / CSMA) was tested respectively. The specific test method was as follows: the polyurethane sheet was cut into 5 cm*2 cm, 100 μL of the composite hydrogel was dripped on one end, and covered with another polyurethane sheet with an overlapping area of 2 cm*2 cm; after photocrosslinking, a 150 g weight was used to press and fit for 15 minutes; then the adhesion performance of the composite hydrogels of Comparative Example 2, Comparative Example 3, and Example 1 was tested using a universal mechanical testing machine. The adhesion performance test was as follows: Figure 3 shown.
[0101] Depend on Figure 3 It can be seen that the bonding strength of the composite hydrogel in Comparative Example 3 is about 21.47±5.22 kPa; after adding dopamine-modified oxidized hyaluronic acid (OHA-DA), the bonding strength of the composite hydrogels in Example 1 and Comparative Example 2 is increased relative to that in Comparative Example 3, indicating that dopamine-modified oxidized hyaluronic acid is conducive to adhesion.
[0102] In addition, the composite hydrogels loaded with Chinese medicine monomers in Examples 2-8 have a bonding strength comparable to that in Example 1, that is, the composite hydrogels loaded with Chinese medicine monomers in Examples 2-8 have good adhesion properties.
[0103] 4. In vitro degradation experiment
[0104] The composite hydrogels in Comparative Example 1 (Hy), Comparative Example 2 (BG / Hy), and Example 1 (Ft1-BG / Hy) were subjected to in vitro degradation experiments. The specific method was as follows: 6 mm*2 mm samples were prepared respectively, and the samples were immersed in phosphate buffered saline (PBS) containing 150 U / mL of lysozyme in a 37°C constant temperature shaker. The soaking liquid of the samples was collected at designated time points (1, 3, 7, 14, 21 d), and the samples were taken out, rinsed with pure water, and freeze-dried and weighed (recorded as Wt); for the samples that continued to degrade, the supernatant was collected every 3 days, and then new liquid was added again. The mass of the composite hydrogel before swelling was W0, and the degradation rate was calculated according to the following formula:
[0105] Degradation rate (%) = (W0 – Wt) / W0 × 100%.
[0106] The in vitro degradation results of the composite hydrogels of Comparative Example 1, Comparative Example 2 and Example 1 are as follows Figure 4 As shown, Figure 4 Figure (a) is a graph showing the degradation rate of the composite hydrogels of Comparative Example 1, Comparative Example 2, and Example 1; Figure 4 Figure (b) is a graph showing pH change of the composite hydrogels of Comparative Example 1, Comparative Example 2, and Example 1.
[0107] Depend on Figure 4 (a) It can be seen that the degradation rate of the composite hydrogel of Comparative Example 1 within 1 day is about 27.88±3.77%, and then the degradation rate slows down, and the degradation rate reaches 44.44±5.56% at 21 days; the degradation rate of the composite hydrogel of Comparative Example 2 and Example 1 is lower than that of Comparative Example 1 within 1 day, but the degradation rate at 7 days is higher than that of Comparative Example 1. At 21 days, the degradation rates of Comparative Example 2 and Example 1 are 57.14±2.53% and 57.98±4.62%, respectively. Figure 4 (b) It can be seen that the pH of Comparative Example 1 is about 7.4; BG is alkaline and increases the pH of the liquid when in contact with PBS. Therefore, the composite hydrogel containing BG (Comparative Example 2 and Example 1) degrades faster in the first 7 days and has a higher pH value; the pH at 14 days and 21 days is close to that of Comparative Example 1.
[0108] In addition, the test found that the composite hydrogel of Comparative Example 3 did not contain dopamine-modified hyaluronic acid, and the degradation rate at 21 days was 32.32%±4.63%, which was much lower than that of Comparative Examples 1-2 and Example 1, indicating that the dopamine-modified oxidized hyaluronic acid in the composite hydrogels of Comparative Examples 1-2 and Example 1 was beneficial to increase the degradation rate.
[0109] The composite hydrogels loaded with traditional Chinese medicine monomers in Examples 2-8 have degradation rates and pH changes comparable to those in Example 1.
[0110] 5. Drug release and ion release experiments
[0111] Drug release and ion release experiments were conducted on Comparative Example 2 (BG / Hy) and Example 1 (Ft1-BG / Hy). The specific test method was as follows: 6mm*2mm samples were prepared respectively, and the samples were immersed in 2mL PBS, in a constant temperature shaker at 37°C, and the old solution was collected at the specified time points (10min, 1h, 4h, 8h, 12h, 1d, 3d, 7d and 21d), and new solution was added again. The Ft1 concentration in the released solution (collected old solution) was quantitatively analyzed by high performance liquid chromatography tandem mass spectrometry (HPLC-MS); the Ca in the released solution was quantitatively analyzed by inductively coupled plasma emission spectrometry (ICP-AES). 2+ 、Si 4+ Perform quantitative analysis.
[0112] The release performance of drugs and ions in the composite hydrogels of Example 1 and Comparative Example 2 is as follows Figure 5 As shown. Among them, Figure 5 The middle (a) figure is a Ca ion release curve; Figure 5 The middle (b) figure is the Si ion release curve; Figure 5 Figure (c) in the middle is the release curve of Panax notoginseng saponin Ft1.
[0113] Depend on Figure 5 As shown in Figures (a) and (b), after the BG in the composite hydrogels of Example 1 and Comparative Example 2 came into contact with the liquid, Ca was rapidly released. 2+ 、Si 4+ .Depend on Figure 5 As shown in Figure (c), the Ft1-BG / Hy group can slowly release Ft1.
[0114] The composite hydrogels loaded with traditional Chinese medicine monomers in Examples 2-8 have active ion and drug release properties comparable to those in Example 1.
[0115] 6. Cytocompatibility test
[0116] The composite hydrogels of Comparative Example 1 (Hy), Comparative Example 2 (BG / Hy) and Example 1 (Ft1-BG / Hy) were respectively immersed in basal medium (DMEM or endothelial cell culture medium (ECM)) for 24 hours, the extract was collected, serum and double antibody were added, and then diluted step by step to obtain the extraction medium. Rat bone marrow mesenchymal stem cells (rBMSCs) or human umbilical vein endothelial cells (HUVECs) were inoculated in 96-well plates at a density of 2000 per well, and replaced with extraction medium after adherent culture for 8-12 hours, and the medium was replaced every other day. After culturing for a period of time, the supernatant was discarded, 100 μL CCK-8 working solution was added, and after incubation in a cell incubator for 1 hour, the absorbance value of each well was detected by an ELISA instrument at a wavelength of 450 nm.
[0117] The proliferation of rBMSCs cells in the composite hydrogel extracts of Comparative Examples 1-2 and Example 1 is shown in Figure 6 As shown, Figure 6 Figure (a) shows the proliferation of rBMSCs cells after co-culture with the composite hydrogel extract for 1 day. Figure 6 Middle (b) shows the proliferation of rBMSCs cells after co-culture with the composite hydrogel extract for 3 days; Figure 6 Figure (c) shows the proliferation of rBMSCs cells after co-culture with the composite hydrogel extract for 7 days; the OD value on the vertical axis represents the absorbance; 1 / 2, 1 / 4, 1 / 8, 1 / 16, and 1 / 32 represent the dilution ratios of each group of materials, respectively; con is the cell culture medium.
[0118] The proliferation of HUVECs cells in the composite hydrogel extracts of Comparative Examples 1-2 and Example 1 is shown in Figure 7 As shown, Figure 7 Figure (a) shows the proliferation of HUVECs cells after co-culture with the composite hydrogel extract for 1 day. Figure 7 Figure (b) shows the proliferation of HUVECs cells after co-culture with the composite hydrogel extract for 3 days; the OD value on the vertical axis represents the absorbance; 1 / 2, 1 / 4, 1 / 8, 1 / 16, and 1 / 32 represent the dilution ratios corresponding to each group of materials, respectively; CON is the cell culture medium (blank control group).
[0119] Depend on Figure 6 It can be seen that after co-culture of rBMSCs with the composite hydrogel extract for 1 day, 3 days and 7 days, the extracts of the Hy, BG / Hy and Ft1-BG / Hy groups had no cytotoxicity compared with the blank control group; and the 1 / 2 diluted concentration DMEM extract of each group showed a proliferation-promoting effect compared with the blank control group (p < 0.5, the difference was statistically significant).
[0120] Depend on Figure 7 It can be seen that after HUVECs were co-cultured with the composite hydrogel extract for 1 day and 3 days, the extracts of the Hy, BG / Hy and Ft1-BG / Hy groups had no cytotoxicity compared with the blank control group. Subsequently, the 1 / 2 diluted concentration material extract was used for in vitro osteogenic differentiation and vascularization performance experiments.
[0121] The above shows that the composite hydrogel of Example 1 has good cell compatibility, and the composite hydrogels loaded with traditional Chinese medicine monomers of Examples 2-8 also have good cell compatibility.
[0122] 7. In vitro osteogenic differentiation performance
[0123] The preparation method of the extract is the same as that of the cell compatibility test. 4rBMSCs were seeded on a 48-well plate, and after 8-12 hours, the osteogenic induction extracts (1 / 2) of Comparative Example 1 (Hy), Comparative Example 2 (BG / Hy) and Example 1 (Ft1-BG / Hy) were replaced, and the blank control group was osteogenic induction solution. Alkaline phosphatase (ALP) staining and Alizarin red (ARS) staining were performed on the 7th and 14th days of culture, respectively.
[0124] Comparative Examples 1-2 and Example 1: The in vitro osteogenic differentiation performance of the composite hydrogels Figure 8 As shown, the upper row is ALP staining images, and the lower row is ARS staining images.
[0125] Depend on Figure 8 It can be seen that in the ALP staining diagram, the staining area of the Ft1-BG / Hy group is larger and darker in color than those of the blank control group, Hy group and BG / Hy group; there is little difference in staining between the blank control group and the Hy group; in the ARS staining diagram, the calcium deposition in the Ft1-BG / Hy group is more than that in the other three groups, and the calcium deposition effect is obvious; this indicates that the composite hydrogel of Example 1 has good osteogenic differentiation performance.
[0126] The composite hydrogels loaded with traditional Chinese medicine monomers in Examples 2-8 have osteogenic differentiation properties comparable to those in Example 1, that is, they also have good osteogenic differentiation properties.
[0127] 8. In vitro angiogenesis performance
[0128] The preparation method of the extract is the same as that of the HUVEC cell compatibility test. Add the matrix gel to a 96-well plate, shake the plate until the gel is evenly distributed throughout the well, and place it in a cell culture incubator for 1 hour to solidify the matrix gel; use HUVECs to plant HUVECs at a concentration of 2*104 per well on the matrix gel-containing plate, add the extract (1 / 2) of the composite hydrogel of Comparative Example 1 (Hy), Comparative Example 2 (BG / Hy) and Example 1 (Ft1-BG / Hy), and the blank control group is the cell culture medium. After 6 and 8 hours of culture, remove the culture medium, stain with ECM culture medium containing 2μM calcein acetoxymethyl ester (calcein AM), and take pictures and record with a fluorescence microscope.
[0129] The results of the in vitro angiogenesis performance of the composite hydrogels of Comparative Examples 1-2 and Example 1 are as follows: Fig. 9 As shown, 6h-5x represents the in vitro angiogenesis effect diagram under a 5x objective lens after 6 hours of culture, 6h-10x represents the in vitro angiogenesis effect diagram under a 10x objective lens after 6 hours of culture, 8h-5x represents the in vitro angiogenesis effect diagram under a 5x objective lens after 8 hours of culture, and 8h-10x represents the in vitro angiogenesis effect diagram under a 10x objective lens after 8 hours of culture.
[0130] Depend on Fig. 9It can be seen that the blank control group and comparative example 1 began to show tubule formation at 6 hours, and comparative example 2 and example 1 could observe more obvious tubule formation effect than the blank control group and comparative example 1, and the tubule formation effect was further manifested after incubation for 8 hours, and the BG / Hy group and the Ft1-BG / Hy group showed more excellent effects.
[0131] The composite hydrogels loaded with traditional Chinese medicine monomers in Examples 2-8 have comparable angiogenesis properties to those in Example 1, that is, they also have good angiogenesis properties.
[0132] In summary, the present invention, through the joint action of photosensitive chitosan or photosensitive chitosan derivatives, dopamine-modified oxidized polysaccharides, and inorganic calcium silicon materials, and the composite hydrogel obtained under the action of a crosslinking agent, makes the composite hydrogel have good osteogenic differentiation, vascularization effect, adhesion performance and degradation performance. In addition, the present invention, by loading Chinese medicine monomers in the photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharides and / or inorganic calcium silicon materials, makes the composite hydrogel have good sustained release performance, and can release Chinese medicine monomers that promote bone repair, avoiding the problem of sudden release of drugs that are directly loaded in the hydrogel and cannot continuously provide sufficient bone induction signals, and can also improve the rigidity of the composite hydrogel.
[0133] The above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the protection scope of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. A composite hydrogel, characterized in that: It includes photosensitive chitosan or its derivatives, dopamine-modified oxidized polysaccharide, inorganic calcium silicon material, cross-linking agent and traditional Chinese medicine monomer; The traditional Chinese medicine monomer is loaded in the photosensitive chitosan or its derivative, the dopamine-modified oxidized polysaccharide and / or the inorganic calcium silicon material.
2. The composite hydrogel according to claim 1, characterized in that The photosensitive chitosan derivative includes at least one of photosensitive quaternized chitosan and photosensitive carboxymethyl chitosan.
3. The composite hydrogel according to claim 1, characterized in that The dopamine-modified oxidized polysaccharide includes at least one of dopamine-modified oxidized hyaluronic acid, dopamine-modified oxidized chondroitin sulfate, and dopamine-modified oxidized dextran.
4. The composite hydrogel according to claim 1, characterized in that The inorganic calcium silicon material includes at least one of calcium silicate, bioglass, calcium-doped silicon dioxide, calcium-doped zinc silicate, calcium-doped magnesium silicate, and calcium-doped strontium silicate.
5. The composite hydrogel according to claim 1, characterized in that The Chinese medicine monomer includes at least one of notoginseng saponin, salvianolic acid, quercetin, ginsenoside, icariin, paridis saponin, hesperidin, ferulic acid and curcumin.
6. The composite hydrogel according to any one of claims 1 to 5, characterized in that In the composite hydrogel, the mass fraction of the photosensitive chitosan or its derivative is 0.1-11%.
7. The composite hydrogel according to any one of claims 1 to 5, characterized in that In the composite hydrogel, the mass fraction of the dopamine-modified oxidized polysaccharide is 0.1-11%; and / or the mass fraction of the inorganic calcium silicon material is 0.1-11%; and / or the loading mass fraction of the traditional Chinese medicine monomer is 0.0001-11%.
8. The method for preparing the composite hydrogel according to any one of claims 1 to 7, characterized in that: The following steps are involved: The traditional Chinese medicine monomer is loaded in the photosensitive chitosan or its derivatives, dopamine-modified oxidative active polysaccharide and / or inorganic calcium silicon material to obtain a mixture; then the mixture is mixed with the remaining components and solidified to obtain the composite hydrogel.
9. A bone repair material, characterized in that: The composite hydrogel comprises the composite hydrogel according to any one of claims 1 to 7.
10. Use of the composite hydrogel according to any one of claims 1 to 7 in the preparation of medical materials.
